CVS Health Reports Strong Second Quarter Results

·18 min read

Raises 2021 Full Year EPS And Cash Flow From Operations Guidance

WOONSOCKET, Rhode Island, Aug. 4, 2021 /PRNewswire/ -- CVS Health Corporation (NYSE: CVS) today announced operating results for the three months ended June 30, 2021.

Second Quarter Highlights:

  • Total revenues increased to $72.6 billion, up 11.1% compared to prior year

  • GAAP diluted EPS of $2.10 and Adjusted EPS of $2.42

Year-to-date Highlights:

  • Total revenues increased to $141.7 billion, up 7.3% compared to prior year

  • GAAP diluted EPS of $3.78 and Adjusted EPS of $4.46

  • Generated cash flow from operations of $8.7 billion

  • Repaid $5.4 billion of long-term debt

2021 Full Year Guidance:

  • Raised GAAP diluted EPS guidance range to $6.35 to $6.45 from $6.24 to $6.36

  • Raised Adjusted EPS guidance range to $7.70 to $7.80 from $7.56 to $7.68

  • Raised cash flow from operations guidance range to $12.5 billion to $13.0 billion from $12.0 billion to $12.5 billion

"We delivered another quarter of strong results and once again raised our outlook for the year," said CVS Health President and CEO Karen S. Lynch. "This quarter was highlighted by broad sales and earnings outperformance, as well as sequential operating margin improvement. We continue to play a critical role in helping America prevail against the pandemic while demonstrating the effectiveness of our unique business model, which is focused on meeting customer needs through innovations that make health care more local, affordable and connected."

_____________________________________________

The Company presents both GAAP and non-GAAP financial measures in this press release to assist in the comparison of the Company's past financial performance with its current financial performance. See "Non-GAAP Financial Information" beginning on page 11 and endnotes beginning on page 21 for explanations of non-GAAP financial measures presented in this press release. See pages 12, 13 and 20 for reconciliations of each non-GAAP financial measure used in this release to the most directly comparable GAAP financial measure.

Consolidated Second Quarter Results and Operational Highlights


Three Months Ended

June 30,


Six Months Ended

June 30,

In millions, except per share amounts

2021


2020


Change


2021


2020


Change

Total revenues

$

72,616



$

65,341



$

7,275



$

141,713



$

132,096



$

9,617


Operating income

4,326



4,680



(354)



7,903



8,138



(235)


Adjusted operating income (1)

4,887



5,328



(441)



9,092



9,441



(349)


Net income

2,791



2,986



(195)



5,015



4,998



17


Diluted earnings per share

$

2.10



$

2.26



$

(0.16)



$

3.78



$

3.79



$

(0.01)


Adjusted EPS (2)

$

2.42



$

2.64



$

(0.22)



$

4.46



$

4.55



$

(0.09)


Enterprise prescriptions (3) (4)

774.2



690.3



83.9



1,512.6



1,436.9



75.7


  • Total revenues increased 11.1% for the three months ended June 30, 2021 compared to the prior year driven by growth across all segments.

  • Operating income and adjusted operating income decreased 7.6% and 8.3%, respectively, for the three months ended June 30, 2021 compared to the prior year primarily due to the return of more normalized utilization levels in the Health Care Benefits segment following a significant decrease in utilization during the three months ended June 30, 2020 due to the COVID-19 pandemic. The decrease in both operating income and adjusted operating income in the three months ended June 30, 2021 was partially offset by increased prescription and front store volume, COVID-19 vaccinations and diagnostic testing in the Retail/LTC segment as well as improved purchasing economics and increased pharmacy claims volume in the Pharmacy Services segment during the three months ended June 30, 2021.

  • Interest expense decreased $129 million, or 16.9%, for the three months ended June 30, 2021 compared to the prior year due to lower debt in the three months ended June 30, 2021.

  • The effective income tax rate was 25.3% for the three months ended June 30, 2021 compared to 24.6% for the three months ended June 30, 2020. The increase in the effective income tax rate was primarily due to the absence of the favorable impact associated with the resolution of several state and local income tax matters in the three months ended June 30, 2020, partially offset by the repeal of the non-deductible health insurer fee ("HIF") for 2021.

  • Paid down $2.4 billion of long-term debt, while returning $650 million to shareholders through dividends during the three months ended June 30, 2021. Since the close of the acquisition of Aetna Inc. in November 2018, the Company has repaid a net of $17.6 billion in long-term debt.

  • Administered more than 6 million COVID-19 tests and nearly 17 million COVID-19 vaccines nationwide in the second quarter. The Company maintains a strong commitment to vaccine and testing equity and continues to optimize site locations and targeted outreach initiatives in order to reach vulnerable populations.

  • Launched new Clinical Trial Services business that brings together innovation and expertise to drive greater access to clinical trials and create a more efficient, convenient experience to improve participant retention and research effectiveness. Core capabilities will include precision patient recruitment, innovative options for Phase III/IV clinical trials and real-world evidence studies at CVS Pharmacy locations, in the home, or virtually.

  • Appointed Shawn Guertin as Executive Vice President and Chief Financial Officer, effective May 28, 2021, to help develop financial strategies to drive transformation at CVS Health. Previously, Guertin spent eight years at Aetna Inc. where he was Executive Vice President, Chief Financial Officer and Chief Enterprise Risk Officer.

Health Care Benefits Segment

The Health Care Benefits segment offers a full range of insured and self-insured ("ASC") medical, pharmacy, dental and behavioral health products and services. The segment results for the three and six months ended June 30, 2021 and 2020 were as follows:


Three Months Ended

June 30,


Six Months Ended

June 30,

In millions, except percentages

2021


2020


Change


2021


2020


Change

Total revenues

$

20,525


$

18,468


$

2,057


$

41,008


$

37,666


$

3,342

Adjusted operating income (1)

1,614


3,464


(1,850)


3,396


4,955


(1,559)

Medical benefit ratio ("MBR") (5)

84.1

%


70.3

%


13.8

%


83.6

%


76.4

%


7.2

%

Medical membership (6)







23.5



23.6



(0.1)


























  • Total revenues increased 11.1% for the three months ended June 30, 2021 compared to the prior year primarily driven by growth in the Government Services business, partially offset by the unfavorable impact of the repeal of the HIF for 2021.

  • Adjusted operating income decreased 53.4% for the three months ended June 30, 2021 compared to the prior year. The decrease in adjusted operating income was primarily driven by the deferral of elective procedures and other discretionary utilization in response to the COVID-19 pandemic during the three months ended June 30, 2020.

  • The MBR increased from 70.3% to 84.1% in the three months ended June 30, 2021 compared to the prior year primarily driven by the impact of the COVID-19 pandemic during the three months ended June 30, 2020 described above and the repeal of the HIF for 2021.

  • Medical membership as of June 30, 2021 of 23.5 million decreased 116,000 members compared with March 31, 2021, primarily reflecting declines in Medicaid and Commercial products, partially offset by an increase in Medicare products. The decline in Medicaid membership reflects the loss of a large ASC customer during the three months ended June 30, 2021.

  • The segment experienced favorable development of prior-periods' health care cost estimates during the three months ended June 30, 2021 driven by favorable development in its Government Services business, primarily attributable to first quarter 2021 performance, partially offset by slightly unfavorable development in its Commercial business, primarily attributable to first quarter 2021 performance.

  • Prior years' health care costs payable estimates developed favorably by $709 million during the six months ended June 30, 2021, driven by favorable development in the Company's Government Services and Commercial businesses. This development is reported on a basis consistent with the prior years' development reported in the health care costs payable table in the Company's annual audited financial statements and does not directly correspond to an increase in 2021 operating results.

See the supplemental information on page 15 for additional information regarding the performance of the Health Care Benefits segment.

Pharmacy Services Segment

The Pharmacy Services segment provides a full range of pharmacy benefit management solutions to employers, health plans, government employee groups and government sponsored programs. The segment results for the three and six months ended June 30, 2021 and 2020 were as follows:


Three Months Ended

June 30,


Six Months Ended

June 30,

In millions

2021


2020


Change


2021


2020


Change

Total revenues

$

38,314



$

34,889



$

3,425



$

74,635



$

69,872



$

4,763


Adjusted operating income (1)

1,755



1,327



428



3,262



2,508



754


Total pharmacy claims processed (4) (7)

562.2



505.4



56.8



1,098.1



1,046.8



51.3


Pharmacy network (8)

479.3



425.1



54.2



934.7



886.2



48.5


Mail choice (9)

82.9



80.3



2.6



163.4



160.6



2.8


  • Total revenues increased 9.8% for the three months ended June 30, 2021 compared to the prior year primarily driven by increased pharmacy claims volume, growth in specialty pharmacy and brand inflation, partially offset by continued price compression.

  • Adjusted operating income increased 32.3% for the three months ended June 30, 2021 compared to the prior year primarily driven by improved purchasing economics that reflected products and services of our group purchasing organization that was launched in the second quarter of 2020 and specialty pharmacy (including pharmacy and/or administrative services for providers and 340B covered entities), as well as increased pharmacy claims volume. These increases were partially offset by continued price compression.

  • Total pharmacy claims processed increased 11.2% on a 30-day equivalent basis for the three months ended June 30, 2021 compared to the prior year. The increase was primarily driven by net new business, COVID-19 vaccinations and increased new therapy prescriptions, which were adversely impacted by the COVID-19 pandemic during the three months ended June 30, 2020. Excluding the impact of COVID-19 vaccinations, total pharmacy claims processed increased 8.4% on a 30-day equivalent basis for the three months ended June 30, 2021 compared to the prior year.

See the supplemental information on page 17 for additional information regarding the performance of the Pharmacy Services segment.

Retail/LTC Segment

The Retail/LTC segment fulfills prescriptions for medications, provides patient care programs, sells a wide assortment of health and wellness products and general merchandise, provides health care services through walk-in medical clinics, provides medical diagnostic testing, administers vaccinations and provides pharmacy services to long-term care facilities. The segment results for the three and six months ended June 30, 2021 and 2020 were as follows:


Three Months Ended

June 30,


Six Months Ended

June 30,

In millions

2021


2020


Change


2021


2020


Change

Total revenues

$

24,728



$

21,662



$

3,066



$

48,002



$

44,411



$

3,591


Adjusted operating income (1)

2,049



1,057



992



3,443



2,959



484


Prescriptions filled (4) (7)

394.4



345.4



49.0



769.8



720.5



49.3


  • Total revenues increased 14.2% for the three months ended June 30, 2021 compared to the prior year primarily driven by increased prescription volume, COVID-19 vaccinations and diagnostic testing and higher front store revenues across all product categories. These increases were partially offset by continued pharmacy reimbursement pressure. Prescription and front store volumes during the three months ended June 30, 2020 were adversely impacted by the COVID-19 pandemic, which resulted in lower new therapy prescriptions and reduced front store revenues due to shelter-in-place orders. COVID-19 vaccinations and diagnostic testing contributed nearly a third of the increase in the segment's revenues for the three months ended June 30, 2021 compared to the prior year, as the prior year included an immaterial impact from diagnostic testing and no COVID-19 vaccinations.

  • Adjusted operating income increased 93.9% for the three months ended June 30, 2021 compared to the prior year primarily driven by the increased prescription and front store volume described above, COVID-19 vaccinations and diagnostic testing and a $125 million gain from an anti-trust legal settlement recorded in the three months ended June 30, 2021. These increases were partially offset by continued pharmacy reimbursement pressure. COVID-19 vaccinations and diagnostic testing contributed approximately half of the increase in adjusted operating income for the three months ended June 30, 2021 compared to the prior year.

  • Prescriptions filled increased 14.2% on a 30-day equivalent basis for the three months ended June 30, 2021 compared to the prior year primarily driven by COVID-19 vaccinations, as well as the continued adoption of patient care programs and increased new therapy prescriptions, both of which were adversely impacted by the COVID-19 pandemic during the three months ended June 30, 2020. Excluding the impact of COVID-19 vaccinations, prescriptions filled increased 9.3% on a 30-day equivalent basis for the three months ended June 30, 2021 compared to the prior year.

See the supplemental information on page 18 for additional information regarding the performance of the Retail/LTC segment.

2021 Full Year Guidance

The Company raised its full year 2021 GAAP diluted EPS guidance range to $6.35 to $6.45 from $6.24 to $6.36 and its full year 2021 Adjusted EPS guidance range to $7.70 to $7.80 from $7.56 to $7.68 and raised its full year 2021 cash flow from operations guidance range to $12.5 billion to $13.0 billion from $12.0 billion to $12.5 billion.

The adjustments between GAAP diluted EPS and Adjusted EPS include, as applicable, adding back amortization of intangible assets, integration costs related to the Company's acquisition (the "Aetna Acquisition") of Aetna Inc. ("Aetna") and an acquisition purchase price adjustment outside of the acquisition accounting measurement period.

Teleconference and Webcast

The Company will be holding a conference call today for investors at 8:00 a.m. (Eastern Time) to discuss its second quarter results. An audio webcast of the call will be broadcast simultaneously for all interested parties through the Investor Relations section of the CVS Health website at http://investors.cvshealth.com. This webcast will be archived and available on the website for a one-year period following the conference call.

In addition, the Company will be hosting an Investor Day on December 9, 2021. Additional details will be available in mid-September 2021.

About CVS Health

CVS Health is the leading health solutions company, delivering care in ways no one else can. We reach more people and improve the health of communities across America through our local presence, digital channels and our nearly 300,000 dedicated colleagues – including more than 40,000 physicians, pharmacists, nurses, and nurse practitioners. Wherever and whenever people need us, we help them with their health – whether that's managing chronic diseases, staying compliant with their medications, or accessing affordable health and wellness services in the most convenient ways. We help people navigate the health care system – and their personal health care – by improving access, lowering costs and being a trusted partner for every meaningful moment of health. And we do it all with heart, each and every day. Learn more at www.cvshealth.com.

Cautionary Statement Concerning Forward-Looking Statements

The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by or on behalf of CVS Health Corporation. Statements in this press release that are forward-looking include, but are not limited to, Ms. Lynch's quotation, the information under the heading "2021 Full Year Guidance" and the information included in the endnotes and reconciliations. By their nature, all forward-looking statements are not guarantees of future performance or results and are subject to risks and uncertainties that are difficult to predict and/or quantify. Actual results may differ materially from those contemplated by the forward-looking statements for a number of reasons as described in our Securities and Exchange Commission ("SEC") filings, including those set forth in the Risk Factors section and under the heading "Cautionary Statement Concerning Forward-Looking Statements" in our most recently filed Annual Report on Form 10-K and our Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2021.

You are cautioned not to place undue reliance on CVS Health's forward-looking statements. CVS Health's forward-looking statements are and will be based upon management's then-current views and assumptions regarding future events and operating performance, and are applicable only as of the dates of such statements. CVS Health does not assume any duty to update or revise forward-looking statements, whether as a result of new information, future events, uncertainties or otherwise.

- Tables Follow -

CVS HEALTH CORPORATION

Condensed Consolidated Statements of Operations

(Unaudited)



Three Months Ended

June 30,


Six Months Ended

June 30,

In millions, except per share amounts

2021


2020


2021


2020

Revenues:








Products

$

50,525



$

46,355



$

97,912



$

93,358


Premiums

18,983



16,927



37,943



34,567


Services

2,819



1,875



5,272



3,825


Net investment income

289



184



586



346


Total revenues

72,616



65,341



141,713



132,096


Operating costs:








Cost of products sold

43,520



40,242



84,414



80,589


Benefit costs

15,901



11,751



31,605



26,138


Operating expenses

8,869



8,668



17,791



17,231


Total operating costs

68,290



60,661



133,810



123,958


Operating income

4,326



4,680



7,903



8,138


Interest expense

636



765



1,293



1,498


Other income

(45)



(45)



(95)



(99)


Income before income tax provision

3,735



3,960



6,705



6,739


Income tax provision

944



974



1,690



1,741


Net income

2,791



2,986



5,015



4,998


Net income attributable to noncontrolling interests

(8)



(11)



(9)



(16)


Net income attributable to CVS Health

$

2,783



$

2,975



$

5,006



$

4,982










Net income per share attributable to CVS Health:








Basic

$

2.11



$

2.27



$

3.80



$

3.81


Diluted

$

2.10



$

2.26



$

3.78



$

3.79


Weighted average shares outstanding:








Basic

1,319



1,309



1,316



1,307


Diluted

1,327



1,314



1,325



1,313


Dividends declared per share

$

0.50



$

0.50



$

1.00



$

1.00


CVS HEALTH CORPORATION

Condensed Consolidated Balance Sheets

(Unaudited)


In millions

June 30,
2021


December 31,
2020

Assets:




Cash and cash equivalents

$

7,119



$

7,854


Investments

3,006



3,000


Accounts receivable, net

24,164



21,742


Inventories

16,979



18,496


Other current assets

5,291



5,277


Total current assets

56,559



56,369


Long-term investments

22,136



20,812


Property and equipment, net

12,664



12,606


Operating lease right-of-use assets

20,476



20,729


Goodwill

79,552



79,552


Intangible assets, net

30,080



31,142


Separate accounts assets

4,880



4,881


Other assets

4,817



4,624


Total assets

$

231,164



$

230,715






Liabilities:




Accounts payable

$

11,052



$

11,138


Pharmacy claims and discounts payable

17,225



15,795


Health care costs payable

8,414



7,936


Policyholders' funds

4,567



4,270


Accrued expenses

14,827



14,243


Other insurance liabilities

1,375



1,557


Current portion of operating lease liabilities

1,791



1,638


Current portion of long-term debt

60



5,440


Total current liabilities

59,311



62,017


Long-term operating lease liabilities

18,509



18,757


Long-term debt

59,294



59,207


Deferred income taxes

6,557



6,794


Separate accounts liabilities

4,880



4,881


Other long-term insurance liabilities

6,734



7,007


Other long-term liabilities

2,314



2,351


Total liabilities

157,599



161,014






Shareholders' equity:




Preferred stock




Common stock and capital surplus

46,995



46,513


Treasury stock

(28,252)



(28,178)


Retained earnings

53,331



49,640


Accumulated other comprehensive income

1,170



1,414


Total CVS Health shareholders' equity

73,244



69,389


Noncontrolling interests

321



312


Total shareholders' equity

73,565



69,701


Total liabilities and shareholders' equity

$

231,164



$

230,715


CVS HEALTH CORPORATION

Condensed Consolidated Statements of Cash Flows

(Unaudited)



Six Months Ended

June 30,

In millions

2021


2020

Cash flows from operating activities:




Cash receipts from customers

$

136,621



$

129,218


Cash paid for inventory and prescriptions dispensed by retail network pharmacies

(79,316)



(76,381)


Insurance benefits paid

(31,245)



(26,483)


Cash paid to other suppliers and employees

(14,900)



(14,688)


Interest and investment income received

394



395


Interest paid

(1,263)



(1,407)


Income taxes paid

(1,552)



(230)


Net cash provided by operating activities

8,739



10,424






Cash flows from investing activities:




Proceeds from sales and maturities of investments

3,947



2,710


Purchases of investments

(5,570)



(3,688)


Purchases of property and equipment

(1,315)



(1,190)


Acquisitions (net of cash acquired)

(108)



(768)


Other

72



6


...

Net cash used in investing activities

(2,974)



(2,930)






Cash flows from financing activities:




Proceeds from issuance of long-term debt



3,946


Repayments of long-term debt

(5,423)



(1,016)


Dividends paid

(1,306)



(1,315)


Proceeds from exercise of stock options

330



166


Payments for taxes related to net share settlement of equity awards

(159)



(68)


Other



(16)


Net cash provided by (used in) financing activities

(6,558)



1,697


Net increase (decrease) in cash, cash equivalents and restricted cash

(793)



9,191


Cash, cash equivalents and restricted cash at the beginning of the period

8,130



5,954


Cash, cash equivalents and restricted cash at the end of the period

$

7,337



$

15,145


CVS HEALTH CORPORATION

Condensed Consolidated Statements of Cash Flows

(Unaudited)



Six Months Ended

June 30,

In millions

2021


2020

Reconciliation of net income to net cash provided by operating activities:




Net income

$

5,015



$

4,998


Adjustments required to reconcile net income to net cash provided by operating activities:




Depreciation and amortization

2,263



2,188


Stock-based compensation

232



179


Deferred income taxes and other noncash items

(370)



(101)


Change in operating assets and liabilities, net of effects from acquisitions:




Accounts receivable, net

(2,384)



(2,233)


Inventories

1,517



1,003


Other assets

(145)



(560)


Accounts payable and pharmacy claims and discounts payable

1,702



1,671


Health care costs payable and other insurance liabilities

104



(415)


Other liabilities

805



3,694


Net cash provided by operating activities

$

8,739



$

10,424


Non-GAAP Financial Information

The Company uses non-GAAP financial measures to analyze underlying business performance and trends. The Company believes that providing these non-GAAP financial measures enhances the Company's and investors' ability to compare the Company's past financial performance with its current performance. These non-GAAP financial measures are provided as supplemental information to the financial measures presented in this press release that are calculated and presented in accordance with GAAP. Non-GAAP financial measures should not be considered a substitute for, or superior to, financial measures determined or calculated in accordance with GAAP. The Company's definitions of its non-GAAP financial measures may not be comparable to similarly titled measures reported by other companies.

Non-GAAP financial measures such as consolidated adjusted operating income, adjusted earnings per share (EPS) and adjusted income attributable to CVS Health exclude from the relevant GAAP metrics, as applicable: amortization of intangible assets and other items, if any, that neither relate to the ordinary course of the Company's business nor reflect the Company's underlying business performance.

For the periods covered in this press release, the following items are excluded from the non-GAAP financial measures described above, as applicable, because the Company believes they neither relate to the ordinary course of the Company's business nor reflect the Company's underlying business performance:

  • The Company's acquisition activities have resulted in the recognition of intangible assets as required under the acquisition method of accounting which consist primarily of trademarks, customer contracts/relationships, covenants not to compete, technology, provider networks and value of business acquired. Definite-lived intangible assets are amortized over their estimated useful lives and are tested for impairment when events indicate that the carrying value may not be recoverable. The amortization of intangible assets is reflected in the Company's unaudited GAAP condensed consolidated statements of operations in operating expenses within each segment. Although intangible assets contribute to the Company's revenue generation, the amortization of intangible assets does not directly relate to the underwriting of the Company's insurance products, the services performed for the Company's customers or the sale of the Company's products or services. Additionally, intangible asset amortization expense typically fluctuates based on the size and timing of the Company's acquisition activity. Accordingly, the Company believes excluding the amortization of intangible assets enhances the Company's and investors' ability to compare the Company's past financial performance with its current performance and to analyze underlying business performance and trends. Intangible asset amortization excluded from the related non-GAAP financial measure represents the entire amount recorded within the Company's GAAP financial statements, and the revenue generated by the associated intangible assets has not been excluded from the related non-GAAP financial measure. Intangible asset amortization is excluded from the related non-GAAP financial measure because the amortization, unlike the related revenue, is not affected by operations of any particular period unless an intangible asset becomes impaired or the estimated useful life of an intangible asset is revised.

  • During the three and six months ended June 30, 2021 and 2020, acquisition-related integration costs relate to the Aetna Acquisition. The acquisition-related integration costs are reflected in the Company's unaudited GAAP condensed consolidated statements of operations in operating expenses within the Corporate/Other segment.

  • In June 2021, the Company received $61 million related to a purchase price working capital adjustment for an acquisition completed during the first quarter of 2020. The resolution of this matter occurred subsequent to the acquisition accounting measurement period and is reflected in the Company's unaudited GAAP condensed consolidated statements of operations for the three and six months ended June 30, 2021 as a reduction of operating expenses within the Health Care Benefits segment.

  • The corresponding tax benefit or expense related to the items excluded from adjusted income attributable to CVS Health and Adjusted EPS above. The nature of each non-GAAP adjustment is evaluated to determine whether a discrete adjustment should be made to the adjusted income tax provision.

See endnotes (1) and (2) on page 21 for definitions of non-GAAP financial measures. Reconciliations of each non-GAAP financial measure to the most directly comparable GAAP financial measure are presented on pages 12, 13 and 20.

Reconciliations of Non-GAAP Financial Measures to the Most Directly Comparable GAAP Financial Measures


Adjusted Operating Income

(Unaudited)


The following are reconciliations of consolidated operating income (GAAP measure) to consolidated adjusted operating income, as well as reconciliations of segment GAAP operating income to segment adjusted operating income:



Three Months Ended June 30, 2021

In millions

Health Care

Benefits


Pharmacy

Services


Retail/

LTC


Corporate/

Other


Intersegment

Eliminations


Consolidated

Totals

Operating income (loss) (GAAP measure)

$

1,273



$

1,705



$

1,919



$

(409)



$

(162)



$

4,326


Amortization of intangible assets

402



50



130







582


Acquisition-related integration costs







40





40


Acquisition purchase price adjustment outside of measurement period

(61)











(61)


Adjusted operating income (loss) (1)

$

1,614



$

1,755



$

2,049



$

(369)



$

(162)



$

4,887




Three Months Ended June 30, 2020

In millions

Health Care

Benefits


Pharmacy

Services


Retail/

LTC


Corporate/

Other


Intersegment

Eliminations


Consolidated

Totals

Operating income (loss) (GAAP measure)

$

3,066



$

1,271



$

933



$

(413)



$

(177)



$

4,680


Amortization of intangible assets

398



56



124







578


Acquisition-related integration costs







70





70


Adjusted operating income (loss) (1)

$

3,464



$

1,327



$

1,057



$

(343)



$

(177)



$

5,328




Six Months Ended June 30, 2021

In millions

Health Care

Benefits


Pharmacy

Services


Retail/

LTC


Corporate/

Other


Intersegment

Eliminations


Consolidated

Totals

Operating income (loss) (GAAP measure)

$

2,653



$

3,157



$

3,184



$

(754)



$

(337)



$

7,903


Amortization of intangible assets

804



105



259



1





1,169


Acquisition-related integration costs







81





81


Acquisition purchase price adjustment outside of measurement period

(61)











(61)


Adjusted operating income (loss) (1)

$

3,396



$

3,262



$

3,443



$

(672)



$

(337)



$

9,092




Six Months Ended June 30, 2020

In millions

Health Care

Benefits


Pharmacy

Services


Retail/

LTC


Corporate/

Other


Intersegment

Eliminations


Consolidated

Totals

Operating income (loss) (GAAP measure)

$

4,161



$

2,385



$

2,713



$

(768)



$

(353)



$

8,138


Amortization of intangible assets

794



123



246



1





1,164


Acquisition-related integration costs







139





139


Adjusted operating income (loss) (1)

$

4,955



$

2,508



$

2,959



$

(628)



$

(353)



$

9,441



Adjusted Earnings Per Share

(Unaudited)


The following are reconciliations of net income attributable to CVS Health to adjusted income attributable to CVS Health and calculations of GAAP diluted EPS and Adjusted EPS:



Three Months Ended

June 30, 2021


Three Months Ended

June 30, 2020

In millions, except per share amounts

Total
Company


Per
Common
Share


Total
Company


Per
Common
Share

Net income attributable to CVS Health (GAAP measure)

$

2,783



$

2.10



$

2,975



$

2.26


Amortization of intangible assets

582



0.44



578



0.44


Acquisition-related integration costs

40



0.03



70



0.06


Acquisition purchase price adjustment outside of measurement period

(61)



(0.05)






Tax impact of non-GAAP adjustments

(138)



(0.10)



(155)



(0.12)


Adjusted income attributable to CVS Health (2)

$

3,206



$

2.42



$

3,468



$

2.64










Weighted average diluted shares outstanding



1,327





1,314




Six Months Ended

June 30, 2021


Six Months Ended

June 30, 2020

In millions, except per share amounts

Total
Company


Per
Common
Share


Total
Company


Per
Common
Share

Net income attributable to CVS Health (GAAP measure)

$

5,006



$

3.78



$

4,982



$

3.79


Amortization of intangible assets

1,169



0.88



1,164



0.89


Acquisition-related integration costs

81



0.06



139



0.11


Acquisition purchase price adjustment outside of measurement period

(61)



(0.05)






Tax impact of non-GAAP adjustments

(292)



(0.21)



(315)



(0.24)


Adjusted income attributable to CVS Health (2)

$

5,903



$

4.46



$

5,970



$

4.55










Weighted average diluted shares outstanding



1,325





1,313


Supplemental Information

(Unaudited)


The Company's segments maintain separate financial information, and the Company's chief operating decision maker (the "CODM") evaluates the segments' operating results on a regular basis in deciding how to allocate resources among the segments and in assessing segment performance. The CODM evaluates the performance of the Company's segments based on adjusted operating income, which is defined as operating income (GAAP measure) excluding the impact of amortization of intangible assets and other items, if any, that neither relate to the ordinary course of the Company's business nor reflect the Company's underlying business performance as further described in endnote (1). The Company uses adjusted operating income as its principal measure of segment performance as it enhances the Company's ability to compare past financial performance with current performance and analyze underlying business performance and trends.


The following is a reconciliation of financial measures of the Company's segments to the consolidated totals:



In millions

Health Care

Benefits


Pharmacy

Services (a)


Retail/

LTC


Corporate/

Other


Intersegment

Eliminations (b)


Consolidated

Totals

Three Months Ended












June 30, 2021












Total revenues

$

20,525



$

38,314



$

24,728



$

182



$

(11,133)



$

72,616


Adjusted operating income (loss) (1)

1,614



1,755



2,049



(369)



(162)



4,887


June 30, 2020












Total revenues

18,468



34,889



21,662



86



(9,764)



65,341


Adjusted operating income (loss) (1)

3,464



1,327



1,057



(343)



(177)



5,328














Six Months Ended












June 30, 2021












Total revenues

$

41,008



$

74,635



$

48,002



$

317



$

(22,249)



$

141,713


Adjusted operating income (loss) (1)

3,396



3,262



3,443



(672)



(337)



9,092


June 30, 2020












Total revenues

37,666



69,872



44,411



176



(20,029)



132,096


Adjusted operating income (loss) (1)

4,955



2,508



2,959



(628)



(353)



9,441






















(a)

Total revenues of the Pharmacy Services segment include approximately $2.8 billion and $2.6 billion of retail co-payments for the three months ended June 30, 2021 and 2020, respectively, and $6.2 billion and $6.0 billion of retail co-payments for the six months ended June 30, 2021 and 2020, respectively.

(b)

Intersegment revenue eliminations relate to intersegment revenue generating activities that occur between the Health Care Benefits segment, the Pharmacy Services segment, and/or the Retail/LTC segment. Intersegment adjusted operating income eliminations occur when members of Pharmacy Services Segment clients ("PSS members") enrolled in Maintenance Choice® elect to pick up maintenance prescriptions at one of the Company's retail pharmacies instead of receiving them through the mail. When this occurs, both the Pharmacy Services and Retail/LTC segments record the adjusted operating income on a stand-alone basis.

Supplemental Information

(Unaudited)


Health Care Benefits Segment


The following table summarizes the Health Care Benefits segment's performance for the respective periods:











Change


Three Months Ended

June 30,


Six Months Ended

June 30,


Three Months Ended

June 30,

2021 vs 2020


Six Months Ended

June 30,

2021 vs 2020

In millions, except percentages and basis points ("bps")

2021


2020


2021


2020


$


%


$


%

Revenues:
















Premiums

$

18,968


$

16,913


$

37,910


$

34,534


$

2,055



12.2

%


$

3,376



9.8

%

Services

1,420


1,428


2,813


2,912


(8)



(0.6)

%


(99)



(3.4)

%

Net investment income

137


127


285


220


10



7.9

%


65



29.5

%

Total revenues

20,525


18,468


41,008


37,666


2,057



11.1

%


3,342



8.9

%

Benefit costs

15,954


11,884


31,711


26,400


4,070



34.2

%


5,311



20.1

%

MBR (Benefit costs as a % of premium revenues) (5)

84.1

%


70.3

%


83.6

%


76.4

%


1,380


bps


720


bps

Operating expenses

$

3,298


$

3,518


$

6,644


$

7,105


$

(220)



(6.3)

%


$

(461)



(6.5)

%

Operating expenses as a % of total revenues

16.1

%


19.0

%


16.2

%


18.9

%









Operating income

$

1,273


$

3,066


$

2,653


$

4,161


$

(1,793)



(58.5)

%


$

(1,508)



(36.2)

%

Operating income as a % of total revenues

6.2

%


16.6

%


6.5

%


11.0

%









Adjusted operating income (1)

$

1,614


$

3,464


$

3,396


$

4,955


$

(1,850)



(53.4)

%


$

(1,559)



(31.5)

%

Adjusted operating income as a % of total revenues

7.9

%


18.8

%


8.3

%


13.2

%









Premium revenues (by business):
















Government

$

13,897


$

11,976


$

27,814


$

24,445


$

1,921



16.0

%


$

3,369



13.8

%

Commercial

5,071


4,937


10,096


10,089


134



2.7

%


7



0.1

%































The following table summarizes the Health Care Benefits segment's medical membership for the respective periods:



June 30, 2021


March 31, 2021


December 31, 2020


June 30, 2020

In thousands

Insured


ASC


Total


Insured


ASC


Total


Insured


ASC


Total


Insured


ASC


Total

Medical membership: (6)
























Commercial

3,183



13,541



16,724



3,201



13,584



16,785



3,258



13,644



16,902



3,298



14,179



17,477


Medicare Advantage

2,911





2,911



2,874





2,874



2,705





2,705



2,651





2,651


Medicare Supplement

1,193





1,193



1,146





1,146



1,082





1,082



954





954


Medicaid

2,231



451



2,682



2,184



637



2,821



2,100



623



2,723



1,918



586



2,504


Total medical membership

9,518



13,992



23,510



9,405



14,221



23,626



9,145



14,267



23,412



8,821



14,765



23,586


























Supplemental membership information:





















Medicare Prescription Drug Plan (standalone)

5,704







5,694







5,490







5,575



Supplemental Information

(Unaudited)


The following table shows the components of the change in health care costs payable during the six months ended June 30, 2021 and 2020:



Six Months Ended

June 30,

In millions

2021


2020

Health care costs payable, beginning of period

$

7,936



$

6,879


Less: Reinsurance recoverables

10



5


Health care costs payable, beginning of period, net

7,926



6,874


Acquisition



412


Add: Components of incurred health care costs




Current year

32,183



26,390


Prior years (a)

(709)



(420)


Total incurred health care costs (b)

31,474



25,970


Less: Claims paid




Current year

24,600



20,223


Prior years

6,409



5,704


Total claims paid

31,009



25,927


Add: Premium deficiency reserve

5



29


Health care costs payable, end of period, net

8,396



7,358


Add: Reinsurance recoverables

18



4


Health care costs payable, end of period

$

8,414



$

7,362












(a)

Negative amounts reported for incurred health care costs related to prior years result from claims being settled for amounts less than originally estimated.

(b)

Total incurred health care costs for the six months ended June 30, 2021 and 2020 in the table above exclude (i) $5 million and $29 million, respectively, related to a premium deficiency reserve related to the Company's Medicaid products, (ii) $27 million and $20 million, respectively, of benefit costs recorded in the Health Care Benefits segment that are included in other insurance liabilities on the Company's unaudited condensed consolidated balance sheets and (iii) $99 million and $119 million, respectively, of benefit costs recorded in the Corporate/Other segment that are included in other insurance liabilities on the Company's unaudited condensed consolidated balance sheets.


The following table summarizes the Health Care Benefits segment's days claims payable for the respective periods:



June 30, 2021


March 31, 2021


December 31, 2020


June 30, 2020

Days Claims Payable (10)

48



48



48



57














Supplemental Information

(Unaudited)


Pharmacy Services Segment


The following table summarizes the Pharmacy Services segment's performance for the respective periods:











Change


Three Months Ended

June 30,


Six Months Ended

June 30,


Three Months Ended

June 30,

2021 vs 2020


Six Months Ended

June 30,

2021 vs 2020

In millions, except percentages

2021


2020


2021


2020


$


%


$


%

Revenues:
















Products

$

38,010


$

34,595


$

74,077


$

69,341


$

3,415



9.9

%


$

4,736



6.8

%

Services

304


294


558


531


10



3.4

%


27



5.1

%

Total revenues

38,314


34,889


74,635


69,872


3,425



9.8

%


4,763



6.8

%

Cost of products sold

36,266


33,271


70,789


66,774


2,995



9.0

%


4,015



6.0

%

Gross profit (11)

2,048


1,618


3,846


3,098


430



26.6

%


748



24.1

%

Gross margin (Gross profit as a % of total revenues) (11)

5.3

%


4.6

%


5.2

%


4.4

%









Operating expenses

$

343


$

347


$

689


$

713


$

(4)



(1.2)

%


$

(24)



(3.4)

%

Operating expenses as a % of total revenues

0.9

%


1.0

%


0.9

%


1.0

%









Operating income

$

1,705


$

1,271


$

3,157


$

2,385


$

434



34.1

%


$

772



32.4

%

Operating income as a % of total revenues

4.5

%


3.6

%


4.2

%


3.4

%









Adjusted operating income (1)

$

1,755


$

1,327


$

3,262


$

2,508


$

428



32.3

%


$

754



30.1

%

Adjusted operating income as a % of total revenues

4.6

%


3.8

%


4.4

%


3.6

%









Revenues (by distribution channel):
















Pharmacy network (8)

$

22,918


$

20,536


$

44,811


$

41,636


$

2,382



11.6

%


$

3,175



7.6

%

Mail choice (9)

15,235


14,109


29,483


27,783


1,126



8.0

%


1,700



6.1

%

Other

161


244


341


453


(83)



(34.0)

%


(112)



(24.7)

%

Pharmacy claims processed: (4) (7)
















Total (a)

562.2


505.4


1,098.1


1,046.8


56.8



11.2

%


51.3



4.9

%

Pharmacy network (8)

479.3


425.1


934.7


886.2


54.2



12.7

%


48.5



5.5

%

Mail choice (9)

82.9


80.3


163.4


160.6


2.6



3.2

%


2.8



1.7

%

Generic dispensing rate: (4) (12) (b)
















Total

86.7

%


88.7

%


87.4

%


88.8

%









Pharmacy network (8)

86.9

%


89.3

%


87.7

%


89.4

%









Mail choice (9)

85.5

%


85.7

%


85.6

%


85.7

%









































(a)

Excluding the impact of COVID-19 vaccinations, total pharmacy claims processed increased 8.4% and 3.0% on a 30-day equivalent basis for the three and six months ended June 30, 2021, respectively, compared to the prior year.

(b)

Excluding the impact of COVID-19 vaccinations, the Pharmacy Services segment's total generic dispensing rate increased to 89.0% in both the three and six months ended June 30, 2021.

Supplemental Information

(Unaudited)


Retail/LTC Segment


The following table summarizes the Retail/LTC segment's performance for the respective periods:











Change


Three Months Ended

June 30,


Six Months Ended

June 30,


Three Months Ended

June 30,

2021 vs 2020


Six Months Ended

June 30,

2021 vs 2020

In millions, except percentages

2021


2020


2021


2020


$


%


$


%

Revenues:
















Products

$

23,609


$

21,476


$

46,003


$

43,998


$

2,133



9.9

%


$

2,005



4.6

%

Services

1,119


186


1,953


413


933



501.6

%


1,540



372.9

%

Net investment income



46





%


46



100.0

%

Total revenues

24,728


21,662


48,002


44,411


3,066



14.2

%


3,591



8.1

%

Cost of products sold

17,952


16,220


34,994


32,798


1,732



10.7

%


2,196



6.7

%

Gross profit (11)

6,776


5,442


13,008


11,613


1,334



24.5

%


1,395



12.0

%

Gross margin (Gross profit as a % of total revenues) (11)

27.4

%


25.1

%


27.1

%


26.1

%









Operating expenses

$

4,857


$

4,509


$

9,824


$

8,900